

FORM 8-K/A
(Amendment No. 1)

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

October 2, 2001
(Date of earliest event reported)

DENTSPLY INTERNATIONAL INC
(Exact name of Company as specified in charter)

Delaware 0-16211 39-1434669
(State of Incorporation) (Commission File Number) (IRS Employer Identification No.)

570 West College Avenue, York, Pennsylvania 17405
(Address of principal executive offices) (Zip Code)

(717) 845-7511
(Company's telephone number including area code)

Page 1 of 41
Exhibit Index on Page 39

Item 7. Financial Statements and Exhibits

- (a) The following audited financial statements of the Degussa Dental Group are filed as part of this Current Report on Form 8-K, as amended by Form 8-K/A:

	Page
Report of PricewaterhouseCoopers GmbH.....	4
Report of KPMG Deutsche Treuhand-Gesellschaft AG.....	5

Combined Statements of Income for the nine months ended September 30, 2001 and for the year ended December 31, 2000.....	6
Combined Balance Sheets as of September 30, 2001 and December 31, 2000.....	7
Combined Statements of Equity and Comprehensive Income for the period from January 1, 2000 through September 30, 2001.....	8
Combined Statements of Cash Flows for the nine month period ended September 30, 2001 and for the year ended December 30, 2000.....	9
Notes to Combined Financial Statements.....	10

(b) The following unaudited pro forma combined financial statements are filed as part of this Current Report on Form 8-K, as amended by Form 8-K/A:

	Page
Introduction to Unaudited Pro Forma Combined Financial Statements.....	29
Unaudited Pro Forma Combined Statement of Income for the nine months ended September 30, 2001.....	31
Unaudited Pro Forma Combined Balance Sheet as of September 30, 2001.....	32
Unaudited Pro Forma Combined Statement of Income for the year ended December 31, 2000.....	33
Notes to Unaudited Pro Forma Combined Financial Statements.....	34

- 2.1 Degussa Dental Group Sale and Purchase Agreement, dated May 28/29, 2001 between Degussa AG (Seller) and Dentsply Hanau GmbH & Co. KG, Dentsply Research & Development Corporation and Dentsply EU S.a.r.l. (Purchasers and subsidiaries of the Company) (previously filed).
- 2.2 Series A and Series B Note Purchase Agreement dated March 1, 2001 between the Company and Prudential Insurance Company of America (previously filed).
- 23.1 Consent of Independent Accountants - PricewaterhouseCoopers GmbH.
- 23.2 Consent of Independent Auditors - KPMG Deutsche Treuhand-Gesellschaft AG

Degussa Dental Group
Financial Statements

Report of Independent Accountants

To the Board of Directors and Shareholder of the
Degussa Dental Group:

In our opinion, the accompanying combined balance sheet as of September 30, 2001 and the related combined statement of income, of equity and comprehensive income and of cash flows present fairly, in all material respects, the financial position of Degussa Dental Group at September 30, 2001, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company's management; our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

/s/ PricewaterhouseCoopers GmbH

Stuttgart, Germany
December 10, 2001

4

Independent Auditors' Report

The Board of Directors
Degussa AG:

We have audited the accompanying combined balance sheet of Degussa Dental Group as of December 31, 2000, and the related combined statements of income, equity and comprehensive income, and cash flows for the year then ended. These combined financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these combined financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the combined financial statements referred to above present fairly, in all material respects, the financial position of Degussa Dental Group as of December 31, 2000, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

KPMG Deutsche Treuhand-Gesellschaft Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft

Frankfurt am Main, Germany

September 28, 2001, except as to note 17, which is as of October 2, 2001

5

DEGUSSA DENTAL GROUP
COMBINED STATEMENTS OF INCOME
(euro, in thousands)

	Nine months ended September 30, 2001	Year ended December 31, 2000
Net sales (Note 14)	346,734	489,517
Cost of products sold (Note 14)	224,745	343,256
Gross profit	121,989	146,261
Selling, general and administrative expenses (Note 14)	86,239	123,729
Other operating expense, net	11,984	6,059
Operating income	23,766	16,473
Other income and expenses:		
Interest expense (Note 14)	3,263	4,635
Interest income (Note 14)	(1,293)	(2,717)
Minority interest	98	306
Earnings before income taxes	21,698	14,249
Income taxes (Note 10)	8,447	840
Net income	13,251	13,409

DEGUSSA DENTAL GROUP
COMBINED BALANCE SHEETS
(euro, in thousands)

	September 30, 2001	December 31, 2000
Assets		
Current assets:		
Cash and cash equivalents (Note 14)	6,556	14,677
Accounts and notes receivable-trade, net (Note 3)	55,915	63,593
Receivables from related parties (Note 14)	1,529	10,202
Inventories (Notes 1 and 4)	102,882	111,533
Deferred tax assets	4,145	3,030
Prepaid expenses and other current assets (Note 5)	3,455	13,317
	174,482	216,352
Total current assets		
Property, plant and equipment, net (Notes 1 and 6)	55,669	56,628
Identifiable intangible assets, net (Notes 1 and 7)	34,416	34,138
Costs in excess of fair value of net assets acquired, net (Note 1)	98,608	104,840
Deferred tax assets	5,108	8,282
Other noncurrent assets	2,780	1,807
	371,063	422,047
	371,063	422,047
Liabilities and combined equity		
Current liabilities:		
Current portion of long-term debt (Note 9)	2,662	2,917
Short-term notes payable (Note 9)	20,520	71,764
Accounts payable-trade	11,763	10,856
Payables to related parties (Note 14)	2,420	18,099
Accrued liabilities (Note 8)	22,528	22,509
Income taxes payable	19,914	11,061
Deferred tax liabilities	9,329	10,856
Other current liabilities	9,479	14,078
	98,615	162,140
Total current liabilities		
Long-term debt, excluding current portion (Note 9)	5,886	8,696
Pension obligation (Note 11)	13,460	14,596
Obligations under capital lease, excluding current installments (Note 12)	9,185	9,092
Deferred tax liabilities	15,532	16,278
Other noncurrent liabilities	5,868	5,312
Minority interests in consolidated subsidiaries	837	661
	149,383	216,775
	149,383	216,775
Commitments and contingencies (note 16)		
Combined equity:		
Investments by and advances from Degussa AG	219,049	200,718
Accumulated other comprehensive income	2,631	4,554
	221,680	205,272
Total combined equity		
	371,063	422,047
	371,063	422,047

<FN>

The accompanying notes are an integral part of the combined financial statements.

</FN>

DEGUSSA DENTAL GROUP
COMBINED STATEMENTS OF EQUITY AND COMPREHENSIVE INCOME
(euro, in thousands)

Investments

Accumulated

	by and advances from Degussa AG	other comprehensive income	Combined equity
	-----	-----	-----
Balance as of December 31, 1999	253,949	3,681	257,630
Net activity with Degussa AG (Note 14)	(66,640)	-	(66,640)
Comprehensive income:			
Net income	13,409	-	13,409
Foreign currency translation	-	873	873

Comprehensive income			14,282
	-----	-----	-----
Balance as of December 31, 2000	200,718	4,554	205,272
Net activity with Degussa AG (Note 14)	5,080	-	5,080
Comprehensive income:			
Net income	13,251	-	13,251
Foreign currency translation	-	(1,923)	(1,923)
Comprehensive income			11,328
	-----	-----	-----
Balance as of September 30, 2001	219,049	2,631	221,680
	=====	=====	=====

<FN>

The accompanying notes are an integral part of the combined financial statements.

</FN>

DEGUSSA DENTAL GROUP
COMBINED STATEMENTS OF CASH FLOWS
(euro, in thousands)

	Nine months ended September 30, 2001	Year ended December 31, 2000
	-----	-----
Cash flows from operating activities:		
Net income	13,251	13,409
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	5,203	7,304
Amortization	8,215	10,553
Deferred income taxes	(214)	(10,128)
(Decrease) increase in pension obligation and other non-current liabilities	(580)	6,024
Loss on disposal of property, plant and equipment	584	70
Other non-cash expense	859	3,438
Changes in current operating assets and liabilities, net:		
Receivables from related parties	8,673	(4,532)
Accounts and notes receivable-trade, third parties, net	7,678	(5,800)
Inventories	8,651	(3,414)
Prepaid expenses and other current assets	9,862	(10,095)
Payables to related parties	(15,679)	9,929
Accounts payable-trade, third parties	(3,692)	6,224
Accrued liabilities	19	(3,701)

Income taxes payable	8,853	7,605
Other, net	(797)	1,308
	-----	-----
Net cash provided by operating activities	50,886	28,194
	-----	-----
Cash flows from investing activities:		
Expenditures for identifiable intangible assets	(2,219)	(1,380)
Proceeds from sale of property, plant and equipment	635	663
Capital expenditures	(6,665)	(10,009)
	-----	-----
Net cash used in investing activities	(8,249)	(10,726)
	-----	-----
Cash flows from financing activities:		
Equity distributions to Degussa AG	(2,747)	(7,223)
Equity contributions by Degussa AG	6,968	-
Increase (decrease) in capital lease obligations	93	(327)
Net repayments of long-term borrowings	(2,810)	(2,306)
Net repayments of short-term borrowings	(2,508)	(899)
Net repayments of short-term borrowings, related parties	(48,991)	(2,560)
	-----	-----
Net cash used in financing activities	(49,995)	(13,315)
	-----	-----
Effect of exchange rate changes on cash and cash equivalents	(763)	90
	-----	-----
Net (decrease) increase in cash and cash equivalents	(8,121)	4,243
Cash and cash equivalents at beginning of period	14,677	10,434
	-----	-----
Cash and cash equivalents at end of period	6,556	14,677
	=====	=====

<FN>
The accompanying notes are an integral part of the combined financial statements.
</FN>

DEGUSSA DENTAL GROUP
NOTES TO COMBINED FINANCIAL STATEMENTS
(unless otherwise noted, all amounts are stated in thousands of euro)

NOTE 1 - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Description of Business

Degussa Dental Group ("Degussa Dental" or the "Company") designs, develops and manufactures a broad range of dental products and complete system solutions used in preventative, restorative and orthodontic treatment by dental laboratories, dentists, orthodontists and oral surgeons. Products marketed primarily to dental laboratories include alloys, veneering porcelain, ceramics systems attachments, consumables and laboratory equipment. Products marketed directly to dentists include filling materials, cements, impression materials, local anesthetics and dedicated equipment for the application of the respective materials. Orthodontic products include all necessary appliances for the movement and realignment of teeth, and products marketed to oral surgeons consist of complete systems to replace teeth using artificial roots implanted into the jawbone of a patient. The Company has operations and investments located in Europe, Asia, South America and the United States. Degussa Dental's customers are primarily located in Europe, Asia, and North and South America.

Basis of Presentation

In 2000, Degussa AG commenced a program to focus its operations on core competencies related to the manufacture and distribution of specialty engineered chemical products. In connection with this program, Degussa AG formed Degussa Dental GmbH & Co. KG ("Degussa Dental KG") and DH Zweite Vermögensverwaltungs GmbH ("DH GmbH"). Subsequently, Degussa AG transferred substantially all dental-related investments, operations and activities to Degussa Dental KG and DH GmbH, with the exception of certain retiree pension obligations, which were retained by Degussa AG. Substantially all of the

German-based dental investments, operations and activities were contributed to Degussa Dental KG while non-German-based dental investments, operations and activities were contributed to DH GmbH. Collectively, Degussa Dental KG, DH GmbH, and their majority owned subsidiaries, comprise Degussa Dental.

On May 29, 2001, Degussa AG entered into a sale and purchase agreement to sell Degussa Dental to DENTSPLY International, Inc. ("DENTSPLY"). This transaction closed on October 2, 2001. The combined financial statements are presented on a historical cost basis and do not reflect any adjustments that might be recorded by DENTSPLY in its application of purchase accounting.

The accompanying combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the results of operations and assets and liabilities directly related to Degussa Dental's operations. The accompanying combined financial statements may not necessarily be indicative of the results of operations, financial positions and cash flows of Dental KG and DH GmbH had they operated as separate independent companies for the duration of the periods presented, nor are they an indicator of future performance.

As the businesses in the combined financial statements are included in multiple consolidated tax returns and in multiple tax jurisdictions, the effective tax rate does not reflect the structure and tax strategies that could be in place if the businesses were conducted by a separate legal entity.

The effects of capital transactions between Degussa Dental and Degussa AG are included in "Investments by and advances from Degussa AG" in the accompanying combined balance sheets and statements of equity and comprehensive income.

10

Degussa Dental's operations have been financed partly through contributions from Degussa AG and partially through third-party debt. Prior to the formation of Degussa Dental in July 2000, Degussa AG did not allocate interest charges to the contributed businesses. Accordingly, such interest expense is not included in the accompanying combined statements of income. In connection with the formation of Degussa Dental certain loans with Degussa AG were created. Interest expense associated with those related party loans that accrue interest is included in the accompanying combined statements of income.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

Principles of Combination

The combined financial statements of the Company include all significant entities in which Dental KG or DH GmbH have legal or effective control after completion of the reorganization program described above. All transactions between combined businesses have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and assumptions.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original

maturities of three months or less, including cash pool positions with related parties, to be cash equivalents (see note 14).

Inventories

Inventories are stated at the lower-of-cost-or-market. The cost of precious metals inventories are determined using the last-in, first-out ("LIFO") method while the cost of other inventory components is determined primarily using the average cost method. Cost consists of purchased component costs and manufacturing costs, which are comprised of direct material and labor costs and applicable indirect costs.

Impairment of Long-Lived Assets

The Company accounts for long-lived assets in accordance with the provisions of Statement of Financial Accounting Standard ("SFAS") No. 121, "Accounting for the Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of". This statement requires that long-lived assets and certain identifiable intangibles be reviewed for impairment whenever events or changes in circumstance indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount which the carrying amount exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.

11

Property, Plant and Equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation. Plant and equipment under capital leases are stated at the present value of minimum lease payments. Expenditures for maintenance and repairs are charged to expense as incurred while replacements and major improvements are capitalized.

Depreciation on plant and equipment is recognized using accelerated or straight-line methods over the useful lives of related assets. Useful lives range from 10 to 40 years for buildings and from 3 to 15 years for machinery and equipment.

Identifiable Intangible Assets

Identifiable intangible assets primarily consist of patents, trademarks and capitalized software costs and are amortized on a straight-line basis over their estimated useful lives.

The estimated useful lives are as follows:

	Estimated useful lives (years) -----
Acquired patents	5-20
Acquired trademarks	5-20
Capitalized software	4
Other	3-10

Costs in Excess of Fair Value of Net Assets Acquired

The excess of costs of acquired businesses over the fair value of net

assets acquired ("goodwill") is amortized on a straight-line basis over the expected periods to be benefited, generally 15 years, and is stated net of accumulated amortization of 23.7 million and 17.8 million as of September 30, 2001 and December 31, 2000, respectively. The Company assesses the recoverability of goodwill based on projected undiscounted future operating cash flows of the acquired operation. The amount of goodwill impairment, if any, is measured based on projected discounted future operating cash flows.

Costs of Computer Software Developed or Obtained for Internal Use

Certain external direct costs of materials and services consumed in developing or obtaining internal use computer software and payroll related costs for employees associated with internal-use software projects are capitalized and amortized on a straight-line basis over four years. Software costs of 440 and 1.2 million were capitalized during the nine months and year ended September 30, 2001 and December 31, 2000, respectively. Amortization expense was 308 and 200 for the nine months and year ended September 30, 2001 and December 31, 2000, respectively.

12

Derivative Financial Instruments

In June 1998, the Financial Accounting Standards Board ("FASB") issued SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities". In June 1999, the FASB issued SFAS No. 137, "Accounting for Derivative Instruments and Hedging Activities - Deferral of the Effective Date of FASB Statement No. 133", which amended SFAS No. 133 to delay its effective date by one year. SFAS No. 133 requires that all derivative instruments be recorded in the balance sheet at fair value. Changes in the fair value of derivatives will be recorded each period in earnings or other comprehensive income, depending on whether a derivative is designated as a part of a hedge transaction and, if it is, the type of hedge transaction. In June 2000, the FASB issued SFAS No. 138, "Accounting for Certain Derivative Instruments and Certain Hedge Activities" which amended SFAS No. 133. This statement, as amended by SFAS 137 and SFAS 138, was adopted effective January 1, 2001. The adoption of SFAS 133 did not have a material impact on net income for the nine months ended September 30, 2001.

The Company utilizes derivative financial instruments to manage its exposure related to foreign exchange, interest rate and commodity price fluctuations. The aggregate notional amount and fair value of all derivative instruments was 4.2 million and 53, respectively, as of September 30, 2001 and 1.9 million and 10, respectively, as of December 31, 2000. The Company does not enter into derivatives for trading purposes.

Foreign Currency

Assets and liabilities of foreign subsidiaries where the functional currency is other than the euro are translated at exchange rates as of the respective balance sheet dates. Revenues and expenses of those subsidiaries are translated at the weighted average year-to-date exchange rates of the respective period. The effects of these translation adjustments are included in other comprehensive income and reported as a separate component of combined equity.

Foreign currency transactions are recorded at the exchange rate prevailing at the date of the transaction. Receivables and payables denominated in foreign currencies are remeasured at the exchange rate in effect as of the respective balance sheet dates. Net foreign currency transaction losses of 39 for the nine months ended September 30, 2001 and gains of 47 for the December 31, 2000, are included in other operating expense, net in the accompanying combined statements of income.

Revenue Recognition

Revenue, net of allowances for related discounts, is recognized when finished product is shipped and risks associated with ownership has transferred to the customer.

A significant portion of Degussa Dental's products include precious metals. Market prices of precious metals are highly volatile and can lead to significant fluctuations in the Company's sales prices and gross profit margins (see note 4).

Research and Development Costs

Research and development costs are expensed as incurred. For the nine months ended September 30, 2001 and the year ended December 31, 2000, research and development costs of 11.1 million and 18.1 million, respectively, were included in selling general and administrative expense in the accompanying combined statements of income.

13

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The businesses in the combined financial statements are included in multiple consolidated tax returns and in multiple tax jurisdictions. There is no formal tax allocation agreement between the various Dental businesses and Degussa AG. The tax amounts reflected in the accompanying combined financial statements have been computed as if each of the contributed businesses had filed separate tax returns.

While the legal forms of Degussa Dental KG, and Ducera Dental GmbH & Co. KG ("Ducera") in 2000, were limited partnerships which are not generally subject to German corporation income tax, the income tax expense for these German entities has been presented in the accompanying combined financial statements as if Degussa Dental KG, and Ducera in 2000, were stand-alone corporate entities. Accordingly, the German corporation tax effects normally passed through to Degussa AG are included in the accompanying combined financial statements as if all earnings were distributed currently.

Commitments and Contingencies

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

Minority Interests

Minority interests in the equity and results of the entities controlled by Degussa Dental are shown as a separate item in the combined financial statements. The entities included in the combined financial statements that have minority interests as of September 30, 2001 and December 31, 2000 are as follows:

Minority

Ownership Percentage

Sankin Kogyo K.K., Tokyo	5.6%
Probem S.A., Catanduva	40.0%

New Accounting Standards Not Yet Adopted

In June 2001, the FASB issued SFAS No.141, "Business Combinations", and SFAS No. 142, "Goodwill and Other Intangible Assets". SFAS No. 141 requires the use of the purchase method of accounting for all business combinations initiated after June 30, 2001. SFAS No. 141 also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill and those acquired intangible assets that are required to be included in goodwill. SFAS No. 142 will require that goodwill no longer be amortized, but instead tested for impairment at least annually. SFAS No. 142 will also require recognized other intangible assets to be amortized over their respective estimated useful lives and reviewed for impairment in accordance with SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of". Any recognized intangible asset determined to have an indefinite useful life will not be amortized, but instead tested for impairment until its life is determined to no longer be indefinite.

14

The Company is required to adopt the provisions of SFAS No. 141 and SFAS No. 142 on January 1, 2002, with the exception of the immediate requirement to use the purchase method of accounting for all future business combinations completed after June 30, 2001. Early adoption and retroactive application of these standards is not permitted. However, goodwill, and any intangible asset determined to have an indefinite useful life, that is acquired in a business combination completed after June 30, 2001 will not be amortized. Goodwill and intangible assets acquired in business combinations completed before July 1, 2001 will continue to be amortized until December 31, 2001.

In June 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations". It applies to legal obligations associated with the retirement of long-lived assets that result from the acquisition, construction, development and (or) the normal operation of a long-lived asset, except for certain obligations of lessees. SFAS 143 requires that the fair value of a liability for an asset retirement obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset and subsequently allocated to expense over the asset's useful life. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002.

In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets". SFAS No. 144 retains the current requirement to recognize an impairment loss only if the carrying amounts of long-lived assets to be held and used are not recoverable from their expected undiscounted future cash flows. However, goodwill is no longer required to be allocated to these long-lived assets when determining their carrying amounts. SFAS No. 144 requires that a long-lived asset to be abandoned, exchanged for a similar productive asset, or distributed to owners in a spin-off be considered held and used until it is disposed. However, SFAS No. 144 requires the depreciable life of an asset to be abandoned be revised. SFAS No. 144 requires that long-lived assets to be disposed of by sale be recorded at the lower of their carrying amount or fair value less cost to sell and to cease depreciation (amortization). Therefore, discontinued operations are no longer measured on a net realizable value basis, and future operating losses are no longer recognized before they occur. The provisions of SFAS No. 144 are effective for fiscal years

beginning after December 15, 2001.

The Company is not currently able to determine the potential effects of adopting these new standards.

NOTE 3 - ACCOUNTS AND NOTES RECEIVABLE

The Company sells dental equipment and supplies primarily to the end user. For customers on credit terms, the Company performs ongoing credit evaluation and generally does not require collateral. Accounts and notes receivable-trade are stated net of an allowance for doubtful accounts of 5.4 million and 2.9 million as of September 30, 2001 and December 31, 2000, respectively.

NOTE 4 - INVENTORIES

Inventories consist of the following:

	September 30 2001	December 31, 2000
Finished goods	78,606	92,956
Work-in-process	11,374	8,937
Raw materials and supplies	12,902	9,640
	-----	-----
	102,882	111,533
	=====	=====

15

Inventories stated under the LIFO method are 34.2 million and 55.0 million, respectively. The current cost of LIFO inventories as of September 30, 2001 and December 31, 2000 was greater than the amount at which these inventories were carried in the combined balance sheet by 52.3 million and 89.1 million, respectively.

As a result of LIFO inventory liquidation, earnings before taxes was increased by approximately 15.0 million for the nine months ended September 30, 2001. For the year ended December 31, 2000, earnings before taxes was not effected because there was no LIFO inventory liquidation.

NOTE 5 - PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses relate primarily to advance payments for leases and rental and maintenance contracts.

Other current assets consist primarily of Value Added Tax refunds receivable of 770 and 10.8 million as of September 30, 2001 and December 31, 2000, respectively.

NOTE 6 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consist of the following:

September 30, 2001	December 31, 2000
-----	-----

Assets, at cost:		
Land	19,391	19,248
Buildings and improvements (note 12)	49,682	49,707
Machinery and equipment	62,342	59,708
Construction in progress	977	898
	-----	-----
	132,392	129,561
Less: Accumulated depreciation (note 12)	76,723	72,933
	-----	-----
	55,669	56,628
	=====	=====

16

NOTE 7 - IDENTIFIABLE INTANGIBLE ASSETS

Identifiable intangible assets consist of the following:

	September 30, 2001	December 31, 2000
	-----	-----
Acquired patents	17,792	16,028
Acquired trademarks	21,003	21,003
Capitalized software	2,735	2,570
Other	71	82
	-----	-----
	41,601	39,683
Less: Accumulated amortization	7,185	5,545
	-----	-----
	34,416	34,138
	=====	=====

NOTE 8 - ACCRUED LIABILITIES

Accrued liabilities consist of the following:

	September 30, 2001	December 31, 2000
	-----	-----
Allowance for customer discounts and rebates	6,317	8,366
Personnel expenses	9,373	7,668
Other	6,838	6,475
	-----	-----
	22,528	22,509
	=====	=====

17

NOTE 9 - FINANCING ARRANGEMENTS

Short-term notes payable

September 30, December 31,

	2001	2000
	-----	-----
Notes payable to banks, weighted average interest rate 11.05%	5,151	7,404
Loans payable to Degussa AG	15,369	64,360
	-----	-----
	20,520	71,764
	=====	=====

Degussa Dental has unused lines of credit for short-term financing of 15.9 million as of September 30, 2001. Interest applicable to these lines of credit varies according to market conditions in the country of origin.

Inventory is pledged to secure additional amounts of 50, and the remaining amount is unsecured.

In 2001 the Company repaid loans of 50.0 million net amount to Degussa AG, bearing interest at the European overnight interest rate average, which was outstanding as of December 31, 2000.

Approximately 13 million of the loans payable to Degussa AG as of September 30, 2001 and December 31, 2000 represents a non-interest bearing loan to DH Zweite Vermögensverwaltungsgesellschaft GmbH. No imputed interest expense has been recorded in the accompanying combined financial statements related to this loan.

The remaining balance of loans payable to Degussa AG as of September 30, 2001 is comprised of a 2.3 million loan to the Japanese operating subsidiary which bears interest at 0.2%. This loan expires on October 1, 2001.

18

Long-Term Debt

	September 30, 2001	December 31, 2000
	-----	-----
Notes secured by mortgage payable, weighted average rate 3.51%, due 2002 - 2005	4,741	8,813
Other long term debt secured by letters of comfort from Degussa AG		
Installment loans, weighted average rate 2.61%, due 2002 - 2004	3,807	2,800
	-----	-----
	8,548	11,613
Less: Current portion of long-term debt	2,662	2,917
	-----	-----
	5,886	8,696
	=====	=====

Aggregate maturities of long-term debt are as follows:

Year ending September 30	
2002	2,662
2003	1,699
2004	3,728

2005	367
2006	92

	8,548
	=====

NOTE 10 - INCOME TAXES

The components of earnings before income taxes are as follows:

	Nine months ended September 30, 2001	Year ended December 31, 2000
	-----	-----
Germany	16,004	6,083
Foreign	5,694	8,166
	-----	-----
	21,698	14,249
	=====	=====

The components of income tax expense (benefit) are as follows:

	Nine months ended September 30, 2001	Year ended December 31, 2000
	-----	-----
Current:		
German	8,176	7,395
Foreign	1,316	3,574
	-----	-----
Total	9,492	10,969
	-----	-----
Deferred:		
German	(1,509)	(9,199)
Foreign	464	(930)
	-----	-----
Total	(1,045)	(10,129)
	-----	-----
Total income tax expense	8,447	840
	=====	=====

In 2000, the German government enacted new tax legislation which, among other changes, reduced the statutory corporate tax rate for German companies from 40% on retained earnings and 30% on distributed earnings to a uniform 25% effective for the year beginning January 1, 2001. The effects of the reductions in the tax rate and other tax law changes on the deferred tax assets and liabilities of the Group's German companies were recognized in the year of enactment and resulted in deferred tax benefit of 8.6 million for the year ended December 31, 2000.

Prior to the 2000 tax law changes becoming effective, German corporation tax law applied a split rate imputation system to the income taxation of a corporation and its shareholders. Upon distribution of retained earnings in the form of a dividend, shareholders subject to German tax received a credit

for corporation taxes paid by the corporation on such distributed earnings. In addition, the corporation received a tax refund to the extent such earnings had been initially subjected to a corporation income tax in excess of 30%. The tax refund was also distributed to the shareholder.

In general, prior to 2001, retained (undistributed) German corporate income was initially subject to a federal corporation income tax at a rate of 40% for 2000 plus a surcharge of 5.5% on federal corporate taxes payable. Giving effect to the surcharge, the federal corporate tax rate was 42.2% for the year ended December 31, 2000. Upon distribution of certain retained earnings generated in Germany to shareholders, the corporate income tax rate on the earnings was adjusted to 30%, plus a solidarity surcharge of 5.5% for a total of 31.65%, by means of a refund for taxes previously paid. Under the new German corporate tax system, during a 15 year transition period beginning on January 1, 2001, Degussa Dental will continue to receive a refund or pay additional taxes on the distribution of retained earnings which existed as of December 31, 2000.

As discussed in Note 2, actual income tax expense reflects the amount of distribution of that year's earnings of the German operations. As such, the refund of tax described above is reflected in the income tax expense reconciliation presented below.

For the nine months ended September 30, 2001 and the year ended December 31, 2000, actual income tax expense differed from the amounts computed by applying the German federal corporation income tax rate of 25% for 2001 and 40% for 2000, to earnings before income taxes as a result of the following:

	Nine months ended September 30, 2001	Year ended December 31, 2000
	-----	-----
Expected income tax at statutory federal rate	5,459	5,700
Effect of:		
Trade tax & solidarity tax, net of federal benefit	1,840	2,022
Benefit of distributed rate	-	(1,503)
Tax holiday	-	(782)
Difference book/taxable income	1,107	1,377
Goodwill	-	2,522
Loss for which no tax benefit recognized	663	-
Tax rate change	-	(8,577)
Other	(622)	81
	-----	-----
Actual income tax expense	8,447	840
	=====	=====

The tax effect of temporary differences giving rise to deferred tax assets and liabilities are as follows:

	September 30, 2001	December 31, 2000
	-----	-----
Deferred tax assets:		
Intangible assets	218	984
Property, plant and equipment	437	404
Financial assets	85	942

Inventories	1,793	1,840
Receivables and other current assets	270	427
Pension accruals	3,400	3,232
Other accruals	1,845	1,865
Payables	156	374
Tax loss carryforwards	1,049	1,244
	-----	-----
Total deferred tax assets	9,253	11,312
	=====	=====
Deferred tax liabilities:		
Intangible assets	(11,975)	(13,028)
Financial assets	(2)	-
Property, plant and equipment	(2,396)	(2,438)
Inventories	(10,389)	(11,414)
Receivables and other current assets	(66)	(220)
Other accruals	(33)	(34)
	-----	-----
Total deferred tax liabilities	(24,861)	(27,134)
	=====	=====
Net deferred tax liabilities	(15,608)	(15,822)
	=====	=====

The combined financial statements include certain assets, goodwill and other intangibles, the tax bases of which will remain with Degussa AG upon completion of the sale of Degussa Dental to DENTSPLY. Deferred tax benefits related to this goodwill and other intangibles of 292 and 503 as of September 30, 2001 and December 31, 2000, respectively, have been included in the combined financial statements.

Subsidiaries of the Company in Brazil and Japan have tax loss carry-forwards of 2.9 million as of September 30, 2001, of which 900 expire through 2006 and 2.0 million may be carried forward indefinitely. The Company believes that sufficient future taxable income will be generated by these subsidiaries to realize the benefits of these tax loss carry-forwards.

As no distributions in the foreseeable future from foreign subsidiaries are planned, deferred taxes have not been recorded for these undistributed earnings. If such distributions were to occur, it is expected that the related tax effects would be partially offset by tax benefits generated from the distribution. Undistributed earnings as of September 30, 2001 amounted to 6.9 million.

22

NOTE 11 - BENEFIT PLANS

The Company maintains a number of separate contributory and non-contributory defined benefit pension plans for a significant portion of its hourly and salaried employees. Pension benefits are generally based upon age, salary and years of service.

Unrecognized actuarial gains and losses are amortized over the average remaining service lives of employees.

SFAS No. 87 requires the recognition of a minimum pension liability if a plan's accumulated benefit obligation is greater than the fair value of plan assets. As this is the case for certain foreign plans, 134 and 148 are included in the pension liability as of September 30, 2001 and December 31, 2000, respectively, with corresponding amounts recorded as intangible assets and included in other non-current assets in the accompanying combined balance sheets.

September 30, 2001			December 31, 2000		
German	Foreign	Total	German	Foreign	Total
-----	-----	-----	-----	-----	-----

Reconciliation of Projected Benefit Obligation						
Benefit obligation at beginning of period	8,592	11,593	20,185	7,840	10,860	18,700
Service cost	272	733	1,005	342	876	1,218
Interest cost	399	335	734	490	394	884
Participant contributions	-	27	27	-	58	58
Actuarial (gains) losses	(3)	1,371	1,368	(80)	121	41
Effects of exchange rate changes	-	(107)	(107)	-	-	-
Net transfers to Degussa AG	(2,329)	-	(2,329)	-	-	-
Benefits assumed and paid	(12)	(614)	(626)	-	(716)	(716)
Benefit obligation at end of period	6,919	13,338	20,257	8,592	11,593	20,185
Reconciliation of Plan Assets						
Fair value of plan assets at beginning of period	-	4,639	4,639	-	4,196	4,196
Actual return on assets	-	160	160	-	171	171
Effects of exchange rate changes	-	(16)	(16)	-	-	-
Employer contributions	-	647	647	-	853	853
Participant contributions	-	27	27	-	58	58
Benefits paid	-	(580)	(580)	-	(616)	(616)
Fair value of plan assets at end of period	-	4,877	4,877	-	4,662	4,662
Reconciliation of Funded Status						
Actuarial present value of projected benefit obligations	6,919	13,338	20,257	8,592	11,593	20,185
Plan assets at fair value	-	4,877	4,877	-	4,662	4,662
Funded status	(6,919)	(8,461)	(15,380)	(8,592)	(6,931)	(15,523)
Adjustment to recognize minimum liability	-	(134)	(134)	-	(148)	(148)
Unrecognized net actuarial (gains) losses and transition obligation	(83)	2,137	2,054	13	1,062	1,075
Accrued benefit cost	(7,002)	(6,458)	(13,460)	(8,579)	(6,017)	(14,596)

23

The amounts recognized in the accompanying combined balance sheet are as follows:

	September 30, 2001			December 31, 2000		
	German	Foreign	Total	German	Foreign	Total
Pension obligation	7,002	6,458	13,460	8,579	6,017	14,596
Identifiable intangible assets	-	134	134	-	148	148
Net amount recognized	7,002	6,324	13,326	8,579	5,869	14,448

All of the Company's plans had accumulated benefit obligations that exceeded the fair value of plan assets. The aggregate accumulated benefit obligation for these plans was 14.2 million as of September 30, 2001 and 14.6 million as of December 31, 2000.

	September 30, 2001			December 31, 2000		
	German	Foreign	Total	German	Foreign	Total
Service cost	272	733	1,005	342	876	1,218
Interest cost	1,286	335	1,621	1,928	394	2,322
Expected return on plan assets	-	(160)	(160)	-	(186)	(186)
Net amortization and deferral	-	279	279	(80)	293	213
Net periodic benefit cost	1,558	1,187	2,745	2,190	1,377	3,567

The weighted average assumptions used in accounting for the Company's plans are as follows:

September 30, 2001		December 31, 2000	
German	Foreign	German	Foreign

Discount rate	6.3%	3.9%	6.3%	3.8%
Expected return on plan assets	-	4.6%	-	4.4%
Rate of compensation increase	2.5%	4.7%	2.6%	4.1%

As described in Note 1, certain pension obligations related to retirees were not transferred from Degussa AG upon formation of Degussa Dental. Accordingly, those obligations are not included in the benefit obligation noted above. However, as they are clearly identifiable to Degussa Dental, interest costs on the retiree pension obligation of 0.9 million and 1.4 million are included in net periodic pension cost for the nine months ended September 30, 2001 and the year ended December 31, 2000, respectively.

24

NOTE 12 - LEASES

The Company is obligated under a capital lease with a related party covering its headquarters in Hanau, Germany that expires in 2018. As of September 30, 2001 the gross amount of capital lease obligations of Sankin Kogyo K.K. was 174. Sankin had no lease obligations as of December 31, 2000. As of September 30, 2001 and December 31, 2000, the gross amount of the building and related accumulated amortization recorded under the capital lease were as follows:

	September 30, 2001	December 31, 2000
Buildings	11,758	11,758
Less: Accumulated amortization	2,540	2,294
	9,218	9,464

Amortization of assets held under capital leases was 0.2 million and 0.3 million for the nine months ended September 30, 2001 and the year ended December 31, 2000.

The Company also has several noncancelable operating leases for automobiles and certain office, warehouse, machinery and equipment and manufacturing facilities. These leases generally require the Company to pay all executory costs such as maintenance and insurance.

Rental expense for the nine months ended September 30, 2001 and the year ended December 31, 2000 was 3.8 million and 4.7 million, respectively.

Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) and future minimum capital lease payments as of September 30, 2001 are:

Year ending September 30	Capital leases	Operating leases
2002	1,006	2,591
2003	1,006	1,946
2004	1,006	1,831
2005	1,006	1,657
2006	1,006	1,524
Later years, through 2018	10,615	-
Total minimum lease payments	15,645	9,549

Less: Interest discount	6,039	=====

Present value of net minimum capital lease payments	9,606	
Less: Current installments	421	

Obligations under capital lease, excluding current installments	9,185	=====

NOTE 13 - FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company believes the carrying amounts of cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, income taxes payable and short-term debt approximate fair value due to the short-term nature of these instruments. The Company also believes the carrying amount of long-term debt approximates fair value as the interest rates are either variable or close to current market rates.

NOTE 14 - Related party transactions

In the normal course of business, Degussa Dental conducts transactions with Degussa AG and entities under the direct control of Degussa AG (together, "Related Parties").

The Company maintains its cash in a bank controlled by Degussa AG and participates in a cash pool administered by Degussa AG. Degussa Dental companies that are part of the different euro-cash-pools in Germany and the Netherlands deposit their excess cash in overnight cash-pool accounts at a rate of EONIA minus 0.125%.

In addition, Degussa Dental sells a portion of its products to entities under the direct control of Degussa AG for resale to third parties. Associated amounts receivable from Related Parties as of the respective balance sheet dates consist of the following:

	September 30, 2001	December 31, 2000
	-----	-----
Trade receivables	1,399	6,692
Other receivables	130	3,510
	-----	-----
Total	1,529	10,202
	=====	=====

Related party interest income of 400 and 1.1 million is recorded in the accompanying combined statements of income for the nine months ended September 30, 2001 and the year ended December 31, 2000, respectively.

Degussa Dental buys certain raw materials, primarily precious metals, from entities under the direct control of Degussa AG. Associated liabilities due to related parties as of the respective balance sheet dates consist of the following:

	September 30, 2001	December 31, 2000
	-----	-----
Trade payables	2,420	3,468
Other payables	-	14,631
	-----	-----
Total	2,420	18,099
	=====	=====

For the nine months ended September 30, 2001 and the year ended December 31, 2000 related party interest expense of 1.4 million and 3.1 million, respectively, is recorded in the accompanying combined statements of income.

26

Sale and purchase activity with Related Parties during the nine months ended September 30, 2001 and the year ended December 31, 2000 was as follows:

	2001	2000
	-----	-----
Sales	12,115	15,303
Purchases	136,705	200,512

Historically, Degussa AG has provided services to and incurred costs on behalf of Degussa Dental. The types of services provided include: administrative services, employee benefit administration, insurance, tax services, treasury services, and accounting and reporting. The cost of such services has been allocated based upon service contracts between the relevant parties as well other methods including the use of time estimates, headcount and transaction statistics, working capital ratios and other similar activity-based or financial relationships. Allocated related party expenses of 11.5 million and 17.1 million for the nine months ended September 30, 2001 and the year ended December 31, 2000, respectively, are included in the accompanying combined statements of income.

While management believes the allocations supporting these expenses is reasonable, such expenses may not be indicative of the costs that would have been incurred if Degussa Dental had performed the related functions or received services as a stand-alone entity. It is not practicable to estimate what these expenses would have been had Degussa Dental operated as an unaffiliated entity.

The components of net activity with Degussa AG during the nine months ended September 30, 2001 and the year ended December 31, 2000 are as follows:

	2001	2000
	-----	-----
Creation of short-term debt upon legal formation	-	(64,360)
Interest expense related to pension obligations not transferred upon legal formation	859	1,438
Common costs incurred and paid by Degussa AG	-	2,200
Distributions to Degussa AG	(2,747)	(7,223)

Contributions from Degussa AG	10,225	-
Other	(3,257)	1,305
	-----	-----
	5,080	(66,640)
	-----	-----

27

NOTE 15 - Supplemental Cash flow information

	Nine months ended September 30, 2001	Year ended December 31, 2000
	-----	-----
Interest paid	2,014	2,577
Income taxes paid	3,193	1,947

NOTE 16 - COMMITMENTS, CONTINGENCIES AND SIGNIFICANT RISKS

Degussa Dental is subject to various lawsuits, claims and proceedings arising in the normal course of business. Management believes the ultimate disposition of these matters will not have a material adverse effect on the Company's combined financial position or results of operations or liquidity.

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from historical results include, but are not limited to, significant seasonal fluctuations relating especially to summer vacation effects on dental practices and laboratories in Germany, as well as overall economic developments, both domestic and foreign, and in particular relating to Germany, the United States, Japan and Brazil.

NOTE 17 - SUBSEQUENT EVENT

On October 2, 2001 Degussa AG completed the sale of Degussa Dental to DENTSPLY International, Inc.

28

INTRODUCTION TO UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS

The pro forma financial information for the year ended December 31, 2000 and as of, and for the nine months ended September 30, 2001, relating to DENTSPLY has been prepared on the basis that the acquisition of Friadent GmbH ("Friadent"), the Acquisition of AstraZeneca PLC's dental injectible anesthesia business ("AZ") and the Degussa Dental Acquisition had been completed on January 1, 2000 and taking into account a sale/leaseback of precious metals owned by Degussa Dental. There are certain limitations

relating to the DENTSPLY Pro Forma Financial Information which are described in more detail in the DENTSPLY Pro Forma Financial Information and which include, in particular, the fact that complete stand-alone historical financial information was not available for the business acquired in the AZ Acquisition since that business had not previously been separately identified as an operating unit by AstraZeneca PLC.

These pro forma historical unaudited combined balance sheets and statements of income of DENTSPLY are provided for illustrative purposes only and, because of their nature, may not give a true picture of DENTSPLY's financial position or results.

The pro forma unaudited combined balance sheets and statements of income and other selected financial and statistical information of DENTSPLY do not necessarily reflect the results of operations or financial results of DENTSPLY that would have actually resulted had the acquisitions referred to below been consummated as of the dates indicated and are not intended to project DENTSPLY'S financial condition or results for any future period.

For the purposes of preparing the pro forma unaudited combined financial statements euro amounts appearing in the combined historical financial statements of Degussa Dental have been translated into U.S. dollars using an exchange rate of U.S.\$1.00 = (euro)0.90 for the statement of income for the nine months ended September 30, 2001, U.S.\$1.00 = (euro)0.91 for the balance sheet as of September 30, 2001, and U.S.\$1.00 = (euro)0.93 for the statement of income for the year ended December 31, 2000.

The following unaudited pro forma combined financial statements have been derived from the application of pro forma adjustments to the combined historical financial statements of DENTSPLY and Degussa Dental which are included in this Form 8-K/A The unaudited pro forma combined statement of income for the year ended December 31, 2000 also reflects the application of pro forma adjustments to a sale/leaseback of precious metals owned by Degussa Dental and to the historical financial information of two additional DENTSPLY acquisitions completed in 2001: Friadent GmbH ("Friadent"), a major global dental implant manufacturer, and AstraZeneca's dental injectible anesthesia business ("AZ"). The Friadent historical financial information was derived from Friadent's various operating units' audited statutory financial statements prepared in conformity with their respective country's generally accepted accounting principles ("GAAP") and was consolidated by DENTSPLY Management. Complete stand-alone historical financial information was not available for AZ since the business purchased was a carve-out of the AstraZeneca business and was not separately identified as an operating unit. As a result, the AZ historical financial information was derived from data presented in AZ's sale information memorandum and estimates made by Management.

The unaudited pro forma combined financial statements as at and for the nine months ended September 30, 2001 and for the year ended December 31, 2000 reflect the purchase in October 2001 of Degussa Dental for an expected final purchase price of (euro)576 million or US\$530 million using the exchange rate at closing of 0.92 US\$/euro, as if it had occurred on January 1, 2000 and September 30, 2001 for pro forma income statement and balance sheet purposes, respectively. In addition, the unaudited pro forma combined income statement for the year ended December 31, 2000 reflects the January 12, 2001 purchase of Friadent for DM 220 million or US\$106 million and the March 1, 2001 purchase of AZ for US\$96.5 million, as if they occurred on January 1, 2000.

Based on the unaudited pro forma combined financial information presented, the combined companies would have had assets of U.S.\$1.8 billion, long-term debt of U.S.\$828.2 million and stockholders' equity of U.S.\$593.5 at September 30, 2001. The combined companies would have also had sales of

U.S.\$1.1 billion, net income of U.S.\$88.3 million and diluted earnings per share of U.S.\$1.68 during the nine months ended September 30, 2001 and sales, net income and diluted earnings per share of U.S.\$1.5 billion, U.S.\$91.1 million and U.S.\$1.74, respectively, for the year ended December 31, 2000.. The pro forma adjustments are described in the accompanying notes to the unaudited pro forma combined financial statements. The unaudited pro forma combined financial information does not purport to represent the financial position or results of operations for the combined companies at any future date or for any future periods.

The unaudited pro forma combined financial information, including the notes to the unaudited pro forma combined financial statements, should be read in conjunction with the Company's Form 10-K for the year ended December 31, 2000 and its Form 10-Q for the nine months ended September 30, 2001, filed with the Commission separately, and the combined financial statements of Degussa Dental, including the notes to these statements, included in this Form 8-K/A.

The Friadent, AZ and Degussa Dental acquisitions have been accounted for using the purchase method of accounting. The purchase price of Friadent and AZ, including actual fees and expenses related to the acquisitions, has been allocated to the tangible and identifiable intangible assets and liabilities of Friadent and AZ based upon DENTSPLY's estimate of the fair value of the assets acquired and the liabilities assumed. The remaining purchase price has been allocated to goodwill, which is the excess of cost over the fair value of the net assets acquired, and included in "Costs in excess of fair value of net assets acquired, net" in the unaudited pro forma combined balance sheet. The purchase price for Degussa Dental, including estimated fees and expenses, has been preliminarily allocated to inventory (to record acquired precious metals and other inventories at fair market value), fixed assets, identifiable intangible assets and goodwill, pending the completion of valuations of acquired tangible and intangible assets and liabilities. Goodwill is included in "Cost in excess of businesses acquired, less amortization" in the unaudited pro forma combined balance sheet. The pro forma adjustments directly attributable to the acquisition relate primarily to the allocation of purchase price to the fair value of the net assets acquired and the depreciation and amortization of the fair value adjustments over their estimated useful lives.

The allocation of purchase price for Degussa Dental may be revised when additional information concerning valuations of various tangible and intangible assets and liabilities becomes available. Accordingly, the final purchase price allocation for Degussa Dental could be different from the amounts reflected in the unaudited pro forma combined financial information. In addition, the unaudited pro forma combined financial information gives effect only to the adjustments set forth in the accompanying notes and does not reflect all restructuring costs, nor any potential cost savings or other synergies that DENTSPLY management expects to realize as a result of the acquisitions. Plans are being currently developed to integrate the operations of the companies, which may involve various costs including employee severance expenses and asset write-offs. Some of these costs may be accounted for as accrued liabilities and included in the allocation of the purchase price consideration at the date of the combination. However, the plans are not yet sufficiently advanced to determine the total amount of those costs which would be accounted for as accrued liabilities on the effective date of the combination. To the extent that these costs are not accounted for as accrued liabilities at the date of the combination, a charge may be recorded, which may be material. The total amount of the charge cannot be quantified at this time, but it is expected to be recognized in the period in which the restructuring occurs.

DENTSPLY INTERNATIONAL INC.
 UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME
 FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2001

	DENTSPLY	Degussa Dental (in thousands,	Degussa Dental Pro Forma Adjustments (except per share	Note (1)	Combined DENTSPLY and Degussa Dental
Net sales	\$ 753,805	\$ 310,327	\$ -	j)	\$ 1,064,132
Cost of products sold	357,879	201,147	300	d), j)	559,326
Gross profit	395,926	109,180	(300)		504,806
Selling, general and administrative expenses	266,759	77,184	2,500	e)	346,443
Other operating expense, net	-	10,726	(5,621)	g)	7,205
			2,100	c)	
Restructuring and other costs (income)	5,500	-	-		5,500
Operating income	123,667	21,270	721		145,658
Other income and expenses:					
Interest expense	12,749	2,920	17,460	f)	30,209
			(2,920)	b)	
Interest income	(696)	(1,157)	1,157	b)	(696)
Other expense (income), net	(22,025)	88	-		(21,937)
Income before income taxes	133,639	19,419	(14,976)		138,082
Provision for income taxes	45,990	7,560	(3,775)	i)	49,775
Net income	\$ 87,649	\$ 11,859	\$ (11,201)		\$ 88,307
Earnings per common share:					
Basic	\$ 1.69				\$ 1.71
Diluted	1.67				1.68
Weighted average common shares outstanding:					
Basic	51,742				51,742
Diluted	52,570				52,570

31

DENTSPLY INTERNATIONAL INC.
 UNAUDITED PRO FORMA COMBINED BALANCE SHEET
 AS OF SEPTEMBER 30, 2001

	DENTSPLY	Degussa Dental (in thousands)	Degussa Dental Pro Forma Adjustments	Note (1)	Combined DENTSPLY and Degussa Dental
Assets					
Current Assets:					
Cash and cash equivalents	\$ 11,879	\$ 5,963	\$ (5,963)	b)	\$ 11,879
Accounts and notes receivable-trade, net	146,568	50,860	-		197,428
Accounts receivable from affiliated companies	-	1,391	-		1,391
Inventories, net	163,853	93,581	30,000	c)	217,434
			(70,000)	c)	
Prepaid expenses and other current assets	41,439	6,913	(3,770)	h)	44,582
Total Current Assets	363,739	158,708	(49,733)		472,714
Property, plant and equipment, net	195,217	50,637	6,000	d)	251,854
Identifiable intangible assets, net	172,081	31,305	50,000	e)	253,386
Costs in excess of fair value of net assets acquired, net	434,256	89,694	341,350	g)	775,606
	-	-	(89,694)	g)	
Other noncurrent assets	53,878	7,174	(4,646)	h)	56,406
Total Assets	\$ 1,219,171	\$ 337,518	\$ 253,277		\$ 1,809,966
Liabilities and Stockholders' Equity					
Current Liabilities:					
Accounts payable	\$ 47,515	\$ 10,700	\$ -		\$ 58,215
Accounts payable due to affiliated companies	-	2,201	-		2,201
Accrued liabilities	113,719	20,491	-		134,210
Income taxes payable	46,782	26,599	(15,863)	b)	57,518
Other current liabilities	-	8,622	-		8,622
Notes payable and current portion of long-term debt	1,049	21,086	(21,086)	b)	1,049
Total Current Liabilities	209,065	89,699	(36,949)		261,815
Long-term debt	343,153	5,354	485,000	f)	828,153
			(5,354)	b)	
Deferred income taxes	22,817	14,128	12,220	h)	49,165
Other noncurrent liabilities	48,355	25,936	-		74,291
Total Liabilities	623,390	135,117	454,917		1,213,424

Minority interests in consolidated subsidiaries	2,260	761	-	3,021
Commitments and contingencies				
Stockholders' Equity	593,521	201,640	(201,640)	593,521
Total Liabilities and Stockholders' Equity	\$ 1,219,171	\$ 337,518	\$ 253,277	\$ 1,809,966

32

DENTSPLY INTERNATIONAL INC.
UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME
FOR THE YEAR ENDED DECEMBER 31, 2000

	DENTSPLY	Degussa Dental	Degussa Pro Forma Adjustments	Note (1)	Combined DENTSPLY and Degussa Dental (in thousands, except per share amounts)	Combined AZ and Friadent	Combined AZ and Friadent Pro Forma Adjustments	Note (2)	Combined DENTSPLY, Degussa Dental, AZ and Friadent
Net sales	\$ 899,796	\$ 453,880	\$--	j)	\$1,343,676	\$ 111,613	\$--		\$1,455,289
Cost of products sold	426,202	318,267	400	d)	744,869	54,931	--		799,800
Gross profit	463,594	135,613	(400)		598,807	56,682	--		655,489
Selling, general and administrative expenses	299,734	114,722	3,333	e)	417,789	42,153	1,700	c)	464,768
							3,126	b)	
Other operating expense, net	--	5,618	(7,639)	g)	779	--	--		779
	--	--	2,800	c)					
Restructuring and other costs (income)	(56)	--	--		(56)	--	--		(56)
Operating income	163,916	15,273	1,106		180,295	14,529	(4,826)		189,998
Other income and expenses:									
Interest expense	10,153	4,298	23,280	f)	33,433	629	8,602	d)	42,664
			(4,298)	b)					
Interest income	(862)	(2,519)	2,519	b)	(862)	(384)	--		(1,246)
Other expense (income), net	2,829	284	--		3,113	(607)	--		2,506
Income before income taxes	151,796	13,210	(20,395)		144,611	14,891	(13,428)		146,074
Provision for income taxes	50,780	779	1,209	i)	52,768	6,342	(4,104)	e)	55,006
Net income	\$ 101,016	\$ 12,431	\$ (21,604)		\$ 91,843	\$ 8,549	\$ (9,324)		\$ 91,068
Earnings per common share:									
Basic	\$ 1.95				\$ 1.77				\$ 1.76
Diluted	1.93				1.75				1.74
Weighted average common shares outstanding:									
Basic	51,856				51,856				51,856
Diluted	52,373				52,373				52,373

33

NOTES TO UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS

Acquisition of Degussa Dental

- (1) The process of determining the adjustments necessary to record the assets and liabilities of Degussa Dental at fair value and allocating the excess purchase consideration over fair value of net assets acquired is being carried out. The allocation of the total expected consideration of (euro)576 million, or US\$530 million based on the exchange rate at the closing date of 0.92 US\$/euro, to the assets and liabilities of Degussa Dental will be made on management's best estimates of fair value pending the completion of valuations of acquired tangible and intangible assets and liabilities. In the unaudited pro forma combined financial statements, preliminary fair value adjustments have been recorded related to inventory and identifiable intangible assets for assets acquired from Degussa Dental, pending the completion of valuations. The estimates made in the unaudited pro forma combined balance sheet at September 30, 2001 to record the acquisition of Degussa Dental are described below:

(in thousands)	
Purchase consideration	\$530,000
Costs and fees of the transaction	25,000
Total purchase consideration	555,000 (a)

Less:		
Net book value of Degussa Dental's		
net assets, adjusted for assets and liabilities not assumed and net debt	148,286	
Fair value of Degussa Dental's inventory	30,000	(c)
Fair value of Degussa Dental's fixed assets	6,000	(d)
Fair value of Degussa Dental's identifiable intangible assets	50,000	(e)
Deferred tax changes related to purchase adjustments and acquisition	(20,636)	(h)
Goodwill	\$ 341,350	(g)

(a) The unaudited pro forma combined financial information does not give effect to all restructuring costs, nor any potential cost savings, revenue enhancements, or other synergies that could result from the acquisition of Degussa Dental. Plans are being currently developed to integrate the operations of the combining companies, which may involve some costs including employee severance expenses and asset write-offs. Some of these costs may be accounted for as accrued liabilities and included in the allocation of the purchase price consideration at the date of the combination. To the extent that these costs are not accounted for as accrued liabilities at the date of the combination, an income statement charge may result, which may be material. The total amount of the charge cannot be quantified at this time, but if made it is expected to be recognized in the period in which the restructuring occurs. Management's plans are not yet sufficiently advanced to determine the total amount of those costs which would be accounted for as accrued liabilities on the effective date of the acquisition. To the extent that these costs are accounted for as accrued liabilities and included in the allocation of the purchase price consideration, the amount allocated to goodwill in the unaudited pro forma combined balance sheet would increase.

34

(b) In certain instances, the historical financial statements for DENTSPLY present captions in a more summarized form than Degussa Dental's presentation. In order to have a consistent presentation, Degussa Dental's captions were categorized in conformity with DENTSPLY's presentation. The historical financial statements for Degussa Dental include an income tax liability of \$15.9 million, which was not assumed by DENTSPLY. In addition, the historical financial statements include net third party debt of \$20.5 million (net of cash). The purchase price was based on a debt-free transaction. Any debt existing at closing was assumed by DENTSPLY and reduced the purchase consideration. As the income tax liability was not acquired in connection with the acquisition of Degussa Dental and since the net debt effectively was not acquired, they have been eliminated as pro forma adjustments to the unaudited pro forma combined balance sheet at September 30, 2001. The net interest expense related to these balances has also been eliminated as a pro forma adjustment to the unaudited pro forma combined income statement for the nine months ended September 30, 2001 and for the year ended December 31, 2000.

- (c) Management believes a portion of the excess of fair value over book value of Degussa Dental's net assets is related to inventory and has estimated the excess of fair value over book value of Degussa Dental's reported inventory as of the closing date, including the fair value inventory "step-up" in the unaudited pro forma combined balance sheet. A significant portion of the acquired inventory are precious metals composed primarily of gold, silver, platinum and palladium sold to dental laboratories for the construction of crown and bridge work. The precious metals inventory has been adjusted from its historical cost of approximately \$45 million as of September 30, 2001 to its fair value of approximately \$70 million using the London fixing of prices established by the London Bullion Market Association (LBMA) of October 1, 2001. An adjustment of approximately \$5 million was made to non-precious metals inventory to estimate the step-up to fair value. No adjustment to cost of sales is reflected in the unaudited pro forma combined statements of income for the nine months ended September 30, 2001 and for the year ended December 31, 2000 with respect to any fair value adjustments to Degussa Dental's inventory as any adjustment is considered to be a non-recurring charge directly related to the transaction. However, DENTSPLY will incur approximately \$2.8 million and \$2.1 million in operating lease expenses for the periods ended December 31, 2000 and September 30, 2001, respectively, for the leasing of precious metals. These amounts have been included in the pro forma adjustments.

The Company anticipates selling the precious metals inventory acquired in the Degussa Dental transaction to a third party. As part of the contemplated transaction, DENTSPLY will receive an up-front cash payment of approximately \$70 million in exchange for the precious metals inventory. This up-front cash payment is based on the fair value as of October 1, 2001. DENTSPLY will use the proceeds from the sale of the precious metals to repay a portion of its outstanding debt. Fluctuations in the market price of the precious metals may materially increase or decrease the fair value of the inventory on the date of closing and may impact the proceeds received from the third party.

- (d) DENTSPLY has estimated the fair value of Degussa Dental's fixed assets and has reflected an estimated fair value "step-up" of the fixed assets in the unaudited pro forma combined balance sheet at September 30, 2001, pending the completion of valuations. Depreciation of \$0.3 million and \$0.4 million related to these fair value adjustments has been included in the unaudited pro forma combined statements of income for the nine months ended September 30, 2001 and for the year ended December 31, 2000, respectively, based on a weighted average expected useful life of 15 years.
- (e) DENTSPLY has estimated the fair value of Degussa Dental's identifiable intangible assets which include patents, trademarks and licensing agreements and have reflected an estimated fair value "step-up" of the identifiable intangible assets in the unaudited pro forma combined balance sheet at September 30, 2001, pending the completion of valuations. DENTSPLY amortizes its identifiable intangible assets on a straight-line basis over their estimated useful lives, ranging from 5 to 40 years. The cost of acquired intangible assets will be reduced proportionally when a portion of the asset is disposed of or the asset becomes impaired. Amortization of \$2.5 million and \$3.3 million related to these fair value adjustments has been included in the unaudited pro forma combined statements of income for the nine months ended September 30, 2001 and for the year ended December 31, 2000, respectively, based on a weighted average expected useful life of 15 years.

- (f) Long-term debt has been increased by \$485.0 million to reflect the total purchase consideration of the acquisition of Degussa Dental and

the costs associated with the acquisition less the anticipated proceeds from the sale of the precious metals inventory. Interest expense of approximately \$17.5 million for the nine months ended September 30, 2001 and \$23.3 million for the year ended December 31, 2000 has been recorded in the unaudited pro forma combined statements of income as a result of the Degussa Dental acquisition. DENTSPLY funded the acquisition of Degussa Dental primarily through a long-term eurobond debt offering, supplemented by drawings under its revolving credit facility and private placements of notes. Interest on the long-term debt has been calculated at an assumed interest rate of 4.80 per cent., which reflects the weighted average interest rate that DENTSPLY expects to pay on the eurobond debt and its existing credit facilities. An increase of 0.125 per cent. in the interest rate assumption would increase annual expense by approximately \$0.6 million.

- (g) Since preliminary valuations of the fixed and intangible assets acquired from Degussa Dental are still in process as of the date of the filing of this Form 8-K/A, the entire excess of purchase price over the net assets of Degussa Dental, except for that related to inventory, fixed assets and identifiable intangible assets, has been allocated to goodwill for purposes of the unaudited combined pro forma financial information. The preliminary allocation will change upon completion of the necessary valuations and will change the amortization included in the unaudited pro forma combined statement of income.

In June 2001, the Financial Accounting Standards Board (FASB) changed the model used to account for purchased business combinations. As a result of this change, goodwill related to acquisitions prior to June 30, 2001 will continue to be amortized until January 1, 2002 when amortization will cease and goodwill will be tested for impairment on a periodic basis. Goodwill related to acquisitions occurring subsequent to June 30, 2001, will not be amortized at all. Therefore, amortization on the goodwill created by the Degussa Dental acquisition has not been recognized in the unaudited pro forma combined statements of income for the nine months ended September 30, 2001 and the year ended December 31, 2000 and the goodwill amortization recognized in Degussa Dental's historical financial statements for these periods have been eliminated as pro forma adjustments.

- (h) The Company has provided deferred income taxes of \$12.2 million for temporary differences caused by the allocation of the purchase price, and will assume a portion of Degussa Dental's tax basis in its assets and liabilities. In addition, the Company has reflected changes to Degussa Dental's historical deferred tax assets due to changes in facts and circumstances as a result of the acquisition.
- (i) Income tax expense reflects the tax effects of pro forma adjustments at the federal weighted average statutory rates for each respective period, excluding amortization of non-tax deductible goodwill. As the transaction, in part, was structured as an asset acquisition the basis in certain deferred tax assets and liabilities were not assumed by DENTSPLY. The unaudited pro forma combined statements of income have been adjusted to exclude changes in deferred tax expense recorded by Degussa Dental for the year ended December 31, 2000 and the nine months ended September 30, 2001.
- (j) A significant proportion of Degussa Dental's net sales comprises sales of precious metals. As the value of these sales is dependent on the price of the precious metals which can fluctuate significantly, DENTSPLY intends in future presentations of its financial results to identify separately the precious metals component of its net sales. Net sales excluding precious metals on a pro forma basis would have been approximately U.S.\$167 million and U.S.\$255 million lower than shown for the nine months ended September 30, 2001 and for the year ended December 31, 2000, respectively. Degussa Dental used the LIFO method of accounting for its inventories of precious metals. During the nine months ended September 30, 2001, cost of products sold was decreased by

approximately U.S.\$13.4 million as a result of LIFO inventory liquidation.

NOTES TO UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS

Acquisition of the AstraZeneca Injectable Anaesthesia Business ("AZ") and Friadent GmbH (" Friadent")

- (2) DENTSPLY has made preliminary adjustments to record the assets and liabilities of AZ and Friadent at fair value and has allocated the excess purchase consideration over fair value of net assets acquired. The total consideration has been allocated to the assets and liabilities of AZ and Friadent based on management's best estimates of fair value.
- (a) The related unaudited pro forma combined statement of income does not give effect to any potential cost savings, revenue enhancements, or other synergies that could result from the acquisition of AZ and Friadent. Plans are currently in place to integrate the operations of the combining companies.
- (b) A total of \$109.8 million of the excess fair value over the book value of Friadent's and AZ's net assets is related to identifiable intangible net assets. The excess fair value attributable to identifiable intangible assets relates to Management's determination of the value of Friadent and AZ's patents, trademarks and licensing agreements.

The determination of the fair value of Friadent's identifiable intangible assets is based on a risk-adjusted discounted net future cash flow analysis of its current product portfolio which was performed by an independent valuation firm. For AZ, the vast majority of purchase price is related to a permanent, exclusive and royalty-free license agreement for the AZ dental injectible anaesthetic products and tradenames. Accordingly, substantially all of the AZ purchase price was allocated to identifiable intangible assets. The license has an indefinite life; however, it will be amortized over 40 years for pro forma presentation.

Amortization of \$3.1 million related to the fair value adjustments in the unaudited pro forma combined statement of income for the year ended December 31, 2000 has been included.

DENTSPLY amortizes its identifiable intangible assets on a straight-line basis over their estimated useful lives, ranging from 5 to 40 years. The cost of acquired intangible assets will be reduced proportionally when a portion of the asset is disposed of or the asset becomes impaired.

- (c) A total of \$68.0 million of the excess fair value over book value of Friadent's and AZ's net assets has been allocated to goodwill. This goodwill is amortized over 40 years. Amortization of \$1.7 million for the year ended December 31, 2000 is included in the unaudited pro forma combined statements of income.

In June 2001, the Financial Accounting Standards Board (FASB) changed the model used to account for purchased business combinations. As a result of this change, goodwill related to acquisitions prior to 30th June, 2001 will continue to be amortized until 1st January, 2002 when amortization will cease and goodwill will be tested for impairment on a periodic basis.

- (d) Long-term debt has been increased by \$205.2 million to reflect the consideration paid in the acquisitions of AZ and Friadent, and the costs associated with these acquisitions. Interest expense of

approximately \$8.6 million for the year ended December 31, 2000 has been reflected in the unaudited pro forma combined statement of income as a result of the AZ and Friadent acquisitions. DENTSPLY funded the acquisitions of AZ and Friadent through the issuance of private placement debt and the use of its existing credit facilities. Interest on the debt is calculated at an assumed weighted average interest rate of 4.20 per cent., which reflects the interest rate that DENTSPLY expects to pay on the private placement debt and use of its existing credit facilities. This rate does not differ materially from the historic weighted average interest rates during the period presented. The interest rates on these debt facilities are contractually fixed or are effectively fixed through the use of interest rate swaps.

- (e) Income tax expense reflects the tax effects of pro forma adjustments at the federal weighted average statutory rates, excluding amortization of non-tax deductible goodwill.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY INTERNATIONAL INC
(Company)

/s/ William R. Jellison
William R. Jellison
Senior Vice President,
Chief Financial Officer

Date: December 14, 2001

EXHIBIT INDEX

Sequential Number Description	Page No.
23.1 Consent of Independent Accountants - PricewaterhouseCoopers GmbH.	40
23.2 Consent of Independent Auditors - KPMG Deutsche Treuhand-Gesellschaft AG	41

Consent of Independent Accountants

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-41775, 33-52616, 33-71792, 33-79094, 33-89786, and 333-56093) and Registration Statement on Form S-3 (No. 333-76089) of DENTSPLY International Inc. of our report dated December 10, 2001 relating to the financial statements of Degussa Dental Group, which appears in the Current Report on Form 8-K/A of DENTSPLY International Inc. dated October 2, 2001.

/s/ PricewaterhouseCoopers GmbH

Stuttgart, Germany
December 14, 2001

EXHIBIT 23.2

The Board of Directors
Degussa AG:

We consent to the incorporation by reference in the registration statement (No. 333-76089) on Form S-3 and the registration statements (Nos. 33-41775, 33-52616, 33-71792, 33-79094, 33-89786, and 333-56093) on Form S-8 of Dentsply International, Inc. of our report dated September 28, 2001, except as to note 17, which is as of October 2, 2001, with respect to the combined balance sheet of Degussa Dental Group as of December 31, 2000 and the related combined statements of income, equity and comprehensive income, and cash flows for the year ended December 31, 2000, which report appears in the Form 8-K/A of Dentsply International, Inc. dated October 2, 2001.

/s/ KPMG Deutsche Treuhand-Gesellschaft AG

KPMG Deutsche Treuhand-Gesellschaft
Aktiengesellschaft
Wirtschaftspfungsgesellschaft

Frankfurt, Germany
December 14, 2001